SLC7A1, solute carrier family 7 member 1, 6541

N. diseases: 46; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 Biomarker disease BEFREE In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC). 12584203 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 AlteredExpression disease BEFREE Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues. 12480925 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 AlteredExpression disease BEFREE CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 Biomarker disease CTD_human CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental
0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.300 Biomarker group CTD_human CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.110 GeneticVariation group GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.110 GeneticVariation group BEFREE The incidence of CVD has revealed a statistically significant dose response with the lack of a latent period and with the average ERR Gy = 0.47, 95% CI = 0.31, 0.63, p < 0.001. 28542008 2017
CUI: C0871470
Disease: Systolic Pressure
Systolic Pressure
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0871470
Disease: Systolic Pressure
Systolic Pressure
0.100 GeneticVariation phenotype GWASCAT Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. 30578418 2019
CUI: C0428883
Disease: Diastolic blood pressure
Diastolic blood pressure
0.100 GeneticVariation phenotype GWASCAT Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. 27841878 2017
CUI: C0871470
Disease: Systolic Pressure
Systolic Pressure
0.100 GeneticVariation phenotype GWASCAT Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. 27841878 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 Biomarker group BEFREE The results of the present study indicate that miR-145 functions as a key mediator in the pathogenesis of hypertension via targeting SLC7A1, which suggests that miR-145 is a potential target for the treatment of hypertension. 29434681 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 GeneticVariation group BEFREE Contribution of SLC7A1 genetic variant to hypertension, the TAMRISK study. 23841815 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 GeneticVariation group BEFREE Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension. 19067360 2009
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 Biomarker group BEFREE Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. 17325243 2007
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 GeneticVariation group LHGDN Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. 17325243 2007
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension
0.030 GeneticVariation disease BEFREE The rs41318021 polymorphism in the SLC7A1 gene was not associated with essential hypertension in 50-year-old subjects. 23841815 2013
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension
0.030 GeneticVariation disease BEFREE We previously identified the polymorphism ss52051869 in the 3'UTR of human SLC7A1, and demonstrated that it might participate in the apparent link between altered endothelial function, decreased L-arginine and nitric oxide (NO) metabolism, and a genetic predisposition to essential hypertension. 19067360 2009
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension
0.030 AlteredExpression disease BEFREE In vivo and in vitro measures of L-arginine transport were substantially reduced in the essential hypertension and positive family history groups compared with the negative family history group; however, no difference was detected in peripheral blood mononuclear cell mRNA or protein expression levels for the cationic amino acid transporter CAT-1. 15569830 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.030 Biomarker disease BEFREE In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC). 12584203 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.030 AlteredExpression disease BEFREE Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues. 12480925 2002
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.030 Biomarker disease BEFREE These findings are the first to implicate a Ca(2+) channel in PCa progression and suggest that CaT1 may be a novel target for therapy. 11401523 2001
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.020 Biomarker disease BEFREE In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1. 31478245 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.020 Biomarker phenotype BEFREE In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1. 31478245 2019